BioCentriq, Inc., a New Jersey-based CDMO for cell and gene therapies, has just concluded a study to evaluate the viability, transfection efficiency, and post-transfection growth of T-cells using Kytopen’s Flowfect® technology. The study results are expected to provide insights into the successful transfection of T-cells with GFP mRNA.
BioCentriq and Kytopen recently joined forces to discover if efficient, non-viral production of cell therapies could be executed in days instead of weeks. Last week, their findings were made public in a white paper titled Efficient, Large-Scale Transfection of T-Cells Using Flowfect® Technology, released during Advanced Therapies Week. This breakthrough could revolutionize the production of cell therapies, and marks a momentous milestone for the field.
BioCentriq’s process development team conducted an intriguing study where cells were transfected with mRNA encoding GFP and analyzed using flow cytometry to measure transfection efficiency. Fascinatingly, the results obtained from this study could help to further our understanding of gene expression and regulation.
Transfection is a powerful tool used in cell engineering that allows scientists to modify gene expression and study its effects. However, old-school transfection methods, like static electroporation, can be damaging to the cell, resulting in low delivery efficiency and stunted cell growth. Fortunately, modern researchers are finding more efficient and less damaging methods for transfection.
The collaboration between BioCentriq and Kytopen to maximize the potential of their Flowfect® technology has yielded groundbreaking results that the industry can now benefit from. Alex Klarer, VP of Business Strategy and Innovation at BioCentriq, expressed his pride in being able to make these results available to the public.
Kytopen’s ex vivo cell engineering platform is revolutionizing the delivery of payloads such as mRNA, DNA, and CRISPR Cas9 RNP to primary cells through its innovative Flowfect® technology. This technology uses a combination of continuous fluid flow and electric fields to deliver payloads with high efficiency and without the harmful effects of traditional transfection via static electroporation. It is the perfect solution for the development of primary cells for immuno-oncology and gene editing applications.
The groundbreaking Flowfect® platform from Kytopen has unlocked the remarkable potential of cells to improve health outcomes. This study is a testament to the platform’s potential for allogeneic and autologous cell therapy applications. According to Kytopen’s Chief Technology Officer Bethany Grant, Ph.D., the Flowfect® platform “can revolutionize the field of cell therapy.”
BioCentriq is a New Jersey-based CDMO for cell and gene therapy, offering a full range of services from process development to clinical manufacturing. Recently purchased by GC of South Korea for $73M, BioCentriq is staffed by over 70 experienced specialists with the expertise and infrastructure needed to produce autologous and allogeneic drug products with the highest quality standards.
Dr. Paulo Garcia and Dr. Cullen Buie, co-founders of MIT startup Kytopen, are revolutionizing the gene-modified cell therapy landscape with their Flowfect® solution. This innovative technology combines microfluidics and automation to make the discovery, development, and manufacturing of these therapies easier, faster, and more cost-effective than current state-of-the-art solutions. Kytopen’s Flowfect® technology is the result of the co-founders’ co-invented proprietary technology, and is set to revolutionize the industry.